C
CHRS
Coherus
1.730
-0.010-0.57%After Hours: 1.738 +0.008 +0.48%17:23 04/02 EDT
OPEN/PREV CLOSE1.700/1.740
TODAY RANGE1.685-1.755
VOL537.25K
MARKET CAP259.31M
52 WEEK RANGE0.7100-2.616
AVG VOL (3M)2.25M
% TURNOVER0.36%
TURNOVER--
P/E (TTM)1.206
% RANGE4.04%
EPS(TTM)1.434
P/E(FORWARD)-1.5319
P/B3.435
BVPS0.5036
DIVIDEND--
P/S4.970
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP214.60M
SHARES OUTSTANDING149.89M
NEXT EARNINGS05/11-05/15
FREE FLOAT124.05M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
TipRanks·1d ago
Coherus BioSciences Charts Leaner Path After Earnings Call
TipRanks·03/10 10:26
Coherus: Strategic Oncology Pivot and Loqtorzi Growth Drive Buy Rating
Seeking Alpha·03/10 00:58
Coherus outlines $175M annualized LOQTORZI target by 2028 as commercial expansion accelerates
TipRanks·03/09 20:40
Coherus Oncology reports Q4 EPS (34c), consensus (31c)
Reuters·03/09 20:31
CORRECTED-Coherus Oncology Q4 revenue misses estimates
Seeking Alpha·03/09 20:23
Coherus BioSciences Non-GAAP EPS of -$0.34 misses by $0.03, revenue of $12.7M misses by $1.39M
Benzinga·03/09 20:18
Insights into Coherus Oncology Q4 Earnings
Dow Jones·03/09 20:15
*Coherus Oncology 4Q Loss/Shr 31c >CHRS
Same Industry
Name/Symbol
Change%
Price
Contact Us
Contact Number :+852 3852 8500Monday 7:00 AM - Saturday 9:00 AM (HKT)
Service Email :service@webull.hkOnline Support: Monday - Friday: 9:00 - 16:00; 22:30 - 5:00 (HKT)
Business Cooperation :marketinghk@webull.hkRisk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language
English
©2026 Webull Securities Limited. All rights reserved.